Appropriate chemopreventive strategy for anti-tubercular therapy related liver injury is unsettled: Results from a systematic review and network meta-analysis

References

• Global tuberculosis report 2019. Geneva: World Health Organization, 2019.
   Google Scholar
• Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: World Health Organization, 2017.
   Google Scholar
• Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192–202.
   PubMed Web of Science ®Google Scholar
• Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle. 1978;59(1):13–32.
   PubMedGoogle Scholar
• Dawra S, Mandavdhare HS, Singh H, et al. Extra-abdominal involvement is associated with antitubercular therapy-related hepatitis in patients treated for abdominal tuberculosis. Clin Exp Hepatol. 2019;5(1):60–64.
   PubMed Web of Science ®Google Scholar
• Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999;281(11):1014–1018.
   PubMed Web of Science ®Google Scholar
• Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta analysis. Chest. 1991;99(2):465–471.
   PubMed Web of Science ®Google Scholar
• Page KR, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006;166(17):1863–1870.
   PubMedGoogle Scholar
• Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–952.
   PubMed Web of Science ®Google Scholar
• EASL clinical practice guidelines: drug induced liver injury. J Hepatol. 2019;70(6):1222–1261.
   PubMed Web of Science ®Google Scholar
• Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol. 2013;3(1):37–49.
   PubMedGoogle Scholar
• Soni H, Kumar-M P, Mishra S, et al. Risk of hepatitis with various reintroduction regimens of anti-tubercular therapy: a systematic review and network meta analysis. Expert Rev Anti Infect Ther. 2020;18(2):171–179.
   PubMed Web of Science ®Google Scholar
• Nagarajan S, Whitaker P. Management of adverse reactions to first-line tuberculosis antibiotics. Curr Opin Allergy Clin Immunol. 2018;18(4):333–341. PMID: 29901473. .
   PubMed Web of Science ®Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–784.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non randomized studies of interventions. BMJ. 2016;355:i4919.
   PubMed Web of Science ®Google Scholar
• Gu J, Tang SJ, Tan SY, et al. An open-label, randomized and multi-center clinical trial to evaluate the efficacy of Silibinin in preventing drug-induced liver injury. Int J Clin Exp Med. 2015;8(3):4320–4327.
   PubMed Web of Science ®Google Scholar
• Luangchosiri C, Thakkinstian A, Chitphuk S, et al. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. BMC Complement Altern Med. 2015;15:334.
   PubMed Web of Science ®Google Scholar
• Marjani M, Baghaei P, Kazempour Dizaji M, et al. Evaluation of hepatoprotective effect of silymarin among under treatment tuberculosis patients: a randomized clinical trial. Iran J Pharm Res. 2016;15(1):247–255.
   PubMed Web of Science ®Google Scholar
• Heo E, Kim DK, Oh SH, et al. Effect of prophylactic use of silymarin on anti-tuberculosis drugs induced hepatotoxicity. Tuberc Respir Dis (Seoul). 2017;80(3):265–269.
   PubMed Web of Science ®Google Scholar
• Baniasadi S, Eftekhari P, Tabarsi P, et al. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol. 2010;22(10):1235–1238.
   PubMed Web of Science ®Google Scholar
• Farazi A, Sofian M, Jabbarias M. Efficacy of N-acetylcysteine on prevention of antituberculosis drug-induced hepatotoxicity. World J Med Sci. 2015;12(4):413–418.
   Google Scholar
• Cheng S. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur Respir J. 2016;48:PA2716.
   Web of Science ®Google Scholar
• Dange SV, Shah KU, Bulakh PM, et al. Efficacy of stimuliv, an indigenous compound formulation, against hepatotoxicity of antitubercular drugs–a double blind study. Indian J Chest Dis Allied Sci. 1992;34(4):175–183.
   PubMedGoogle Scholar
• Adhvaryu MR, Reddy N, Vakharia BC. Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach. World J Gastroenterol. 2008;14(30):4753–4762.
   PubMed Web of Science ®Google Scholar
• Gulati K, Ray A, Vijayan VK. Assessment of protective role of polyherbal preparation, Livina, against anti-tubercular drug induced liver dysfunction. Indian J Exp Biol. 2010;48(3):318 22.
   PubMed Web of Science ®Google Scholar
• Tabarsi P, Fahimi F, Heidarzadeh N, et al. The effect of garcin® in preventing antiTB induced hepatitis in newly diagnosed tuberculosis patients. Iran J Pharm Res. 2014;13(Suppl):169–176.
   PubMed Web of Science ®Google Scholar
• Emrani Z, Shojaei E, Khalili H. Ginger for prevention of antituberculosis-induced gastrointestinal adverse reactions including hepatotoxicity: a randomized pilot clinical trial. Phytother Res. 2016;30(6):1003–1009.
   PubMed Web of Science ®Google Scholar
• Hatamkhani S, Khalili H, Karimzadeh I, et al. Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized clinical trial. J Gastroenterol Hepatol. 2014;29(5):997–1004.
   PubMed Web of Science ®Google Scholar
• Hasanain AFA, Zayed AAH, Mahdy RE, et al. Cholecalciferol for prophylaxis against antituberculosis therapy-induced liver disorders among naïve patients with pulmonary tuberculosis: A randomized, comparative study. Int J Mycobacteriol. 2017;6(2):149–155.
   PubMed Web of Science ®Google Scholar
• Xian YS, Wang ZR, Gong XF, et al. Clinical study on Ganbi decoction in treating antituberculotic agent-caused liver injury. Chin J Integr Med. 2006;12(2):107–111.
   PubMedGoogle Scholar
• Azuma J, Ohno M, Kubota R, et al. Pharmacogenetics-based tuberculosis therapy research group. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol. 2013;69(5):1091–1101.
   PubMed Web of Science ®Google Scholar
• Chu NH, Li L, Zhang X, et al. Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease. Int J Tuberc Lung Dis. 2015;19(4):475–480.
   PubMed Web of Science ®Google Scholar
• Zhang S, Pan H, Peng X, et al. Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: A randomized controlled trial. J Gastroenterol Hepatol. 2016;31(2):409–416.
   PubMed Web of Science ®Google Scholar
• Chen Y, Ye P, Ren C, et al. Pharmacoeconomics of three therapeutic schemes for anti-tuberculosis therapy induced liver injury in China. Open Med (Wars). 2018;13:53–63.
   PubMedGoogle Scholar
• Marjani M, Fahim F, Sadr M, et al. Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial. Gastroenterol Hepatol Bed Bench. 2019;12(2):138–142.
   PubMedGoogle Scholar
• Amagon KI, Awodele O, Akindele AJ. Methionine and vitamin B-complex ameliorate antitubercular drugs-induced toxicity in exposed patients. Pharmacol Res Perspect. 2017;5(5):e00360.
   Web of Science ®Google Scholar
• Stine JG, Lewis JH. Current and future directions in the treatment and prevention of drug induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol. 2016;10(4):517–536.
   PubMed Web of Science ®Google Scholar
• Nabi T, Nabi S, Rafiq, et al. Role of N-acetylcysteine treatment in non-acetaminophen induced acute liver failure: A prospective study. Saudi J Gastroenterol. 2017;23(3):169–175.
   PubMed Web of Science ®Google Scholar
• Tao L, Qu X, Zhang Y, et al. Prophylactic therapy of silymarin (Milk Thistle) on antituberculosis drug-induced liver injury: a meta-analysis of randomized controlled trials. Can J Gastroenterol Hepatol. 2019 Jan 10;2019:3192351. .
   PubMed Web of Science ®Google Scholar
• Liu Q, Garner P, Wang Y, et al. Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies. BMC Public Health. 2008;8:365.
   PubMed Web of Science ®Google Scholar
• Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015;17(1):14. .
   PubMed Web of Science ®Google Scholar
• Danan G, Benichou C. Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323–1330.
   PubMed Web of Science ®Google Scholar
• Teschke R, Danan G. Worldwide use of RUCAM for causality assessment in 81,856 Idiosyncratic DILI and 14,029 HILI cases published 1993-mid 2020: a comprehensive analysis. Medicines (Basel). 2020;7(10):E62.
   PubMedGoogle Scholar
• Danan G, Teschke R. Roussel Uclaf causality assessment method for drug-induced liver injury: present and future. Front Pharmacol. 2019;10:853.
   PubMed Web of Science ®Google Scholar
• Teschke R, Schulze J, Eickhoff A, et al. Drug induced liver injury: can biomarkers assist RUCAM in causality assessment? Int J Mol Sci. 2017;18(4):803.
   Web of Science ®Google Scholar